Presentations by Event

Presented at ID Week, October 2020

Sulbactam-durlobactam (ETX2514) Is Active Against Recent, Multidrug-Resistant Acinetobacter baumannii Clinical Isolates from the Middle East

S. McLeod, S. Moussa, M. Hackel, and A. Miller

Program(s): durlobactam (etx2514)

A Novel β-lactamase Inhibitor (Durlobactam, DUR) and β-Lactams Enhance Susceptibility Against MultidrugResistant (MDR) Mycobacterium abscessus (Mab)

Khalid M. Dousa, Sebastian G. Kurz, Christopher R. Bethel, Magdalena Taracilla, Alita A. Miller and Robert A. Bonomo

Program(s): durlobactam (etx2514)

Serious Infections Caused by Carbapenem Susceptible and Carbapenem Resistant Acinetobacter baumannii-calcoaceticus Complex – A Retrospective Review

Khurram Rana, Richard Wunderink, Betty Tsuei, Galia Rahav, Eugenii Kovalchuk, Iftihar Koksal, Kathleen Maloney and Suba Srinivasan

Program(s): durlobactam (etx2514)

In Vitro Activity of Sulbactam-Durlobactam (ETX2514) Against Recent Global Clinical Acinetobacter baumannii-calcoaceticus Complex Isolates

S. McLeod, S. Moussa, M. Hackel, and A. Miller

Program(s): durlobactam (etx2514)

Presented at BAARN, October 2, 2020

An Adventure in Antibacterial Drug Discovery - Competing Methyl Effects on Biochemical Potency and Cell Accumulation

R. Tommasi

Presented at ID Week, Washington DC, October 2019

In vitro Antibacterial Activity and in vivo Efficacy of Sulbactam-Durlobactam (ETX2514) against Pathogenic Burkholderia Species

Alita Miller, ID Week 2019

Program(s): durlobactam (etx2514)

In vitro Antibacterial Activity of Sulbactam Durlobactam (ETX2514) against 121 Recent Acinetobacter baumannii Isolates from Patients in India

Alita Miller, ID Week 2019

Program(s): durlobactam (etx2514)